SCHEMBL31367530

SCHEMBL31367530

Cc1ccc(-c2cn3cc(-c4ccccc4)cc(-c4ccccc4)c3n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 10/20 0.62
SLC2A1 P11166 1/20 0.62
ALDH1A2 O94788 3/20 0.54
ALDH1A1 P00352 6/20 0.53
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
GAA P10253 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
KDM4E B2RXH2 3/20 0.50
TP53 P04637 3/20 0.50
KMT2A Q03164 3/20 0.50
HPGD P15428 2/20 0.50
TSHR P16473 2/20 0.50
HSD17B10 Q99714 2/20 0.50
PKM P14618 1/20 0.50
CDK5 Q00535 1/20 0.50
CDK5R1 Q15078 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31367560 1.00 ALDH1A3 (0.62) ALDH1A3SLC2A1ALDH1A2ALDH1A1NPC1
SCHEMBL31367386 1.00 ALDH1A3 (0.62) ALDH1A3SLC2A1ALDH1A2ALDH1A1NPC1
SCHEMBL31367458 1.00 ALDH1A3 (0.62) ALDH1A3SLC2A1ALDH1A2ALDH1A1NPC1
SCHEMBL31367607 0.91 ALDH1A3 (0.63) ALDH1A3SLC2A1ALDH1A2ALDH1A1NPC1
SCHEMBL31367440 0.87 ALDH1A3 (0.50) ALDH1A3SLC2A1ALDH1A2ALDH1A1NPC1
SCHEMBL31367464 0.87 ALDH1A3 (0.52) ALDH1A3SLC2A1ALDH1A2ALDH1A1NPC1
SCHEMBL31367531 0.87 ALDH1A3 (0.49) ALDH1A3SLC2A1ALDH1A2ALDH1A1NPC1
SCHEMBL31367430 0.86 ALDH1A3 (0.68) ALDH1A3SLC2A1ALDH1A2ALDH1A1NPC1
SCHEMBL31367556 0.86 ADORA1 (0.56) ALDH1A3SLC2A1ALDH1A2ALDH1A1NPC1
SCHEMBL31367441 0.86 ADORA1 (0.56) ALDH1A3SLC2A1ALDH1A2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP claimed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US claimed
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP disclosed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A ALDH2, ALDH3A1, ALDH1A1 ALDH1A3 8/4885SLC2A1 317/4885ALDH1A2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.